<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00776074</url>
  </required_header>
  <id_info>
    <org_study_id>ENG K001 GF</org_study_id>
    <secondary_id>2005-005641-19</secondary_id>
    <secondary_id>EC 406</secondary_id>
    <secondary_id>U1111-1114-2217</secondary_id>
    <nct_id>NCT00776074</nct_id>
  </id_info>
  <brief_title>A Pharmacodynamic Study of Leuprorelin Gelatin-Free Formulation in Female Subjects With Uterine Fibroids.</brief_title>
  <official_title>3 Months, Open-Label, Parallel-Group Study of the Pharmacodynamics, Pharmacokinetics and Safety of TAP-144SR 1-month Depot Gelatin-Free vs. Gelatin-Containing Formulation in Female Patients With Uterine Fibroids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the pharmacodynamics of leuprorelin gelatin free&#xD;
      formulation (GF) to leuprorelin gelatin containing formulation (GC) in female subjects with&#xD;
      uterine fibroids.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gonadotropin-releasing hormone, also called luteinizing hormone releasing hormone, is a&#xD;
      neuropeptide hormone released from the hypothalamus. Gonadotropin-releasing hormone binds to&#xD;
      specific gonadotropin-releasing hormone receptors in the cell membrane of pituitary gland&#xD;
      cells, inducing the cells to produce and release the gonadotropins: luteinizing hormone and&#xD;
      follicle-stimulating hormone. Luteinizing hormone and follicle-stimulating hormone are&#xD;
      released into the general circulation and stimulate the gonads to produce and release the sex&#xD;
      steroids: testosterone and estrogen. Follicle-stimulating hormone also controls&#xD;
      gametogenesis.&#xD;
&#xD;
      Suppression of gonadotropin secretion is an effective treatment for conditions such as&#xD;
      prostate cancer, endometriosis and central precocious puberty, because these conditions&#xD;
      respond to manipulation of the sex steroids. Suppression of gonadotropin secretion can be&#xD;
      achieved by administration of gonadotropin-releasing hormone agonists that, after an initial&#xD;
      transient stimulation of gonadotropin release, reversibly desensitize pituitary&#xD;
      gonadotropin-releasing hormone receptors. Desensitization is thought to occur by&#xD;
      down-regulation of the numbers of gonadotropin-releasing hormone receptors and uncoupling of&#xD;
      the receptors from the biochemical pathway that leads to gonadotropin release. Termination of&#xD;
      gonadotropin-releasing hormone agonist administration reverses the desensitization, and&#xD;
      gonadotropin and sex hormone levels return to normal.&#xD;
&#xD;
      There are several marketed gonadotropin-releasing hormone agonists, one of which is TAP-144&#xD;
      (leuprorelin), an active synthetic nonapeptide gonadotropin-releasing hormone analogue. In&#xD;
      the present study, the existing leuprorelin 1- month sustained release formulation will be&#xD;
      compared with a new gelatin-free 1-month sustained release formulation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of measured E2 (17β-estradiol) Serum Concentrations less than or equal to 30 pg/mL.</measure>
    <time_frame>Weeks 5 through Final Visit.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time course of E2 (17β-estradiol) Serum Concentration levels.</measure>
    <time_frame>At all Visits.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time course of E2 (17β-estradiol) Serum Concentrations less than or equal to 30 pg/mL.</measure>
    <time_frame>Week 5 through Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of E2 (17β-estradiol) Serum Concentration levels less than or equal to 50, 40 and 30 ng/dL.</measure>
    <time_frame>At all Visits.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Uterine Fibroids</condition>
  <arm_group>
    <arm_group_label>Leuprorelin (GF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Leuprorelin (GC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuprorelin (GF)</intervention_name>
    <description>Leuprorelin (GF) 3.75 mg injection, subcutaneously, once every 4 weeks for up to 12 weeks.</description>
    <arm_group_label>Leuprorelin (GF)</arm_group_label>
    <other_name>Leuplin</other_name>
    <other_name>Enantone</other_name>
    <other_name>Trenantone</other_name>
    <other_name>TAP-144SR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuprorelin (GC)</intervention_name>
    <description>Leuprorelin (GC) 3.75 mg injection, subcutaneously, once every 4 weeks for up to 12 weeks.</description>
    <arm_group_label>Leuprorelin (GC)</arm_group_label>
    <other_name>Leuplin</other_name>
    <other_name>Enantone</other_name>
    <other_name>Trenantone</other_name>
    <other_name>TAP-144SR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female patients with measurable uterine fibroids confirmed by vaginal or abdominal&#xD;
             ultrasound, deemed otherwise healthy.&#xD;
&#xD;
          -  A body mass index in the range 18 to 28.&#xD;
&#xD;
          -  Oestradiol, progesterone, luteinizing hormone and follicle stimulating hormone results&#xD;
             within the range of normal ovarian function.&#xD;
&#xD;
          -  Regular menstruation (except for symptoms of fibroids).&#xD;
&#xD;
          -  Females of childbearing potential who are sexually active must agree to use barrier&#xD;
             contraception, and can neither be pregnant nor lactating from Screening throughout the&#xD;
             duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute pelvioperitonitis, ovarian cysts, persistent corpus luteum.&#xD;
&#xD;
          -  History of bilateral oophorectomy, hysterectomy, or hypophysectomy.&#xD;
&#xD;
          -  Clinically relevant abnormal history, physical findings, or laboratory values at the&#xD;
             pre-study screening assessment that could interfere with the objectives of the study&#xD;
             or the safety of the patient.&#xD;
&#xD;
          -  Presence of acute or chronic illness or history of chronic illness sufficient to&#xD;
             invalidate the patient participation in the study or make it unnecessarily hazardous.&#xD;
&#xD;
          -  Impaired endocrine, thyroid, hepatic, respiratory or renal function, diabetes&#xD;
             mellitus, coronary heart disease, or history of any psychotic mental illness.&#xD;
&#xD;
          -  Presence or history of severe adverse reaction to any drug.&#xD;
&#xD;
          -  Participation in other clinical studies of a new chemical entity or a prescription&#xD;
             medicine within the previous 3 months.&#xD;
&#xD;
          -  Presence or history of drug or alcohol abuse, or smoking of more than 10 cigarettes&#xD;
             daily.&#xD;
&#xD;
          -  Evidence of drug abuse on urine testing.&#xD;
&#xD;
          -  Positive test for hepatitis B, hepatitis C, human immune deficiency virus 1 or human&#xD;
             immune deficiency virus 2.&#xD;
&#xD;
          -  Severe bleedings from fibroids.&#xD;
&#xD;
          -  Anemia (hemoglobin less than 11 g/dL), loss of more than 400 mL blood during the 3&#xD;
             months before the study.&#xD;
&#xD;
          -  Use of oral contraceptives or other estrogen containing medication, progestins,&#xD;
             danazol, progesterone antagonists, antiandrogens, steroids or gonadotropins which&#xD;
             might affect sex steroid production or activity or assay (e.g. norethindrone) within&#xD;
             30 days prior to study enrolment.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda Pharma Gmbh, Aachen (Germany)</affiliation>
  </overall_official>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>October 16, 2008</study_first_submitted>
  <study_first_submitted_qc>October 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2008</study_first_posted>
  <last_update_submitted>June 17, 2010</last_update_submitted>
  <last_update_submitted_qc>June 17, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2010</last_update_posted>
  <responsible_party>
    <name_title>Medical Director</name_title>
    <organization>Takeda Pharma Gmbh, Aachen (Germany)</organization>
  </responsible_party>
  <keyword>Leiomyoma</keyword>
  <keyword>Uterine Fibroids</keyword>
  <keyword>Drug Therapy</keyword>
  <keyword>Uterine Neoplasms</keyword>
  <keyword>Fibroid Tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leuprolide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

